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Peripheral vascular complications are common in diabetic patients. While pathogenic 
mechanisms have received much consideration, only recently regenerative processes 
captured attention. There is now a consensus that the bone marrow is a source of 
reparative cells and that this healing mechanism is lost in people with diabetes, 
especially in those suffering from ischemic complications. This failure was thought to 
occur due to a negative impact of diabetes on the mobilization of stem/progenitor cells 
with angiogenic properties from the bone marrow to the circulation. Moreover, those 
patients showing severely reduced bone marrow cell mobilization also bared a very 
high risk for adverse cardiovascular events. More recently, the structural integrity of 
the bone marrow was recognized to be altered because of the rarefaction of local 
microvasculature and innervation, thus mirroring anatomical features that typically 
occur in peripheral tissues. Ensuing hypoxia, nutrient starvation, and creation of an 
acidic and oxidative environment concur in causing the depletion of stem/progenitor 
cells in the endosteal niche and in forcing stromal cells to activate an adipogenesis 
program. Moreover, stem/progenitor cells acquire a pathogenic phenotype and, once 
mobilized, can pass harmful signalling molecules to vascular cells of peripheral tissues 
thereby contributing to ischemic complications. These new pieces of evidence indicate 
that the bone marrow should deserve more attention in the current care of critical limb 
ischemia and diabetic foot. Owing to powerful reserve capacities, the bone marrow 
integrity could be preserved and even rescued using rehabilitation programs and 
pharmacological treatments with consequent benefit for local and whole-organism 
homeostasis. 
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Critical limb-threatening ischemia (CLTI) is a clinical syndrome defined by the 
presence of peripheral artery disease (PAD) in combination with rest pain, gangrene, 
or lower limb ulceration with more than 2 weeks of duration.1 The condition is 
associated with significant morbidity, mortality, and increased utilization of health care 
resources.2 The risk of major amputation due to CLTI is higher in patients with diabetes 
mellitus (DM) than CLTI patients without DM.3, 4 Diabetes was highly prevalent in 
recently conducted randomized controlled trials in CLTI patients, such as the 
JUVENTAS (Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-
Arterial Supplementation) trial.5 A sub-analysis of the JUVENTAS trial confirmed that, 
among patients with DM, the risk of amputation is higher in those with more severe 
ischemia at initial presentation.6 
 In this review article, we critically analyse the available evidence on the 
participation of the bone marrow (BM) in the pathogenesis of advanced vasculopathy 
in patients with diabetes. We report seminal data showing BM-derived circulating cells 
have proangiogenic properties that are lost in people with diabetes. Next, we refer to 
studies pinpointing a new pathologic phenomenon, for which the term mobilopathy 
was coined. This consists of the deficient liberation of BM cells as a result of a 
disrupted chemokine gradient within the BM and between the BM and the circulation. 
Importantly, the recognition of mobilopathy has fuelled the formulation of new 
predictors of adverse cardiovascular outcomes in people of DM.  Finally, we report 
new findings highlighting that the BM of people with DM is affected by typical 
complications such as microangiopathy and neuropathy, which profoundly disturb the 
correct function of the marrow niche. Stem cells (SCs) and progenitor cells (PCs) 




transmissible to the peripheral microvasculature. Therefore, we believe that, as 
highlighted in the title of this review, the BM is target and accomplice of vascular 
complications in DM. 
 
BM structural organization 
The BM is the major reservoir for hematopoietic stem/progenitor cells (HSPCs). The 
marrow environment is not homogeneous. It comprises specialized 
microenvironments (niches) that correspond to stages of HSPC maturation, under the 
influence of an orchestrated network of soluble signals and surface interactions.7 
HSPCs characterized by high self-renewal capacity are localized near the endosteum 
and move to the bone marrow sinusoids as they mature. Endosteal stromal cells, 
endothelial cells of vascular sinusoids, and adventitial perisinusoidal cells support 
hematopoiesis through paracrine signalling and physical interactions. Moreover, BM 
vascular cells preside the regular trafficking of HSPCs to the systemic circulation and 
back to the BM. Importantly, both niches are highly innervated. Sympathetic 
innervation regulates both the acute and circadian release of HSPCs.8 Moreover, this 
neuronal mechanism is responsive to pharmacological modulation, as for granulocyte-
colony stimulating factor (G-CSF) whose administration induces HSPC mobilization, 
at least in part through indirect activation of noradrenergic receptors.9 
 
The detrimental effect of DM on BM-derived angiogenic cells 
The first demonstration of a damaging effect of DM on BM-derived cells was obtained 
on ill-defined cell populations, thought to be direct precursors of endothelial cells and 
endowed of proangiogenic activity in culture; therefore, named endothelial progenitor 




circulating immature cells expressing the surface marker CD34 in combination with 
the vascular endothelial growth factor-A (VEGF-A) receptor-2 (VEGFR-2).11 This 
pioneering paper inspired the new paradigm that hematopoiesis and angiopoiesis 
were mutually interactive phenomena and that the BM may play fundamental roles in 
vascular regenerative processes. The prevailing view was that EPCs generated in the 
BM could be mobilized following a gradient of growth factors and chemokines released 
by ischemic or injured tissues, reach the damaged tissue, and differentiate into 
endothelial cells. It is now clear that EPCs are not true progenitor cells, but belong to 
the category of myeloid cells, which support vascular growth mainly by secreting 
proangiogenic factors. Likewise, mesenchymal stromal cells and HSPCs 
subpopulations, including those expressing the surface marker CD34, can exert 
proangiogenic activities via paracrine mechanisms.12, 13  
 
Diabetic mobilopathy 
As mentioned above, there is regular physiological trafficking of HSPCs and other BM 
cells to the circulation. These patrolling cells are thought to participate in the 
homeostasis of peripheral vasculature and in sensing environmental signals that 
require BM reactions. A much more robust and forced mobilization occurs in response 
to peripheral injury and is governed by changes in the local concentration of 
chemokines. For instance, the CXC chemokine CXCL12 plays key roles in 
hematopoiesis, angiogenesis and inflammation. These actions are mediated by the 
binding of CXCL12 to the cognate CXCR4 and CXCR7 receptors on HSPCs and 
leukocytes.14 High BM levels of CXCL12 retain those cells in the endosteal 
environment, whereas an inversion of the CXCL12 gradient results in cell mobilization 




stimulating factor (GM-CSF), are used to mobilize HSPCs into the circulation and 
harvest them for therapies in cancer patients. G-CSF induces the mobilization of 
HSPCs through its direct effects on macrophages and β-adrenergic sympathetic 
nerves, resulting in the dynamic modulation of the CXCL12 gradient between the 
endosteal and vascular niche.   
Ferraro et al. were the first to report that DM alters the ability of sympathetic 
nerves to mediate the G-CSF–induced HSPC mobilization.15 Another fundamental 
study in a large population with coronary artery disease showed that reduced 
circulating levels of HSPCs, identified for the expression of the cell surface marker 
CD34, are associated with risk of death in people with DM.16 A definitive meta-analysis 
of 21 studies, comprising 4,155 individuals, confirmed this association.17 Together with 
the notion that CD34+ cells maintain cardiovascular health, these studies suggest that 
an impaired liberation of reparative proangiogenic cells from BM to the circulation may 
be implicated in the increased cardiovascular vulnerability of diabetic patients.18 Other 
conditions and risk factors, such as arterial hypertension and smoking, are 
characterized by a defect in HSPC mobilization,19, 20 but, for none of them, such a strict 
association with risk of death has been reported. 
 
Molecular mechanisms of mobilopathy 
Mechanistic studies indicate that DM contributes in impairing BM cell mobilization via 
dysregulation of the key lifespan determinant pathway comprising the silent 
information regulator (SIR)T1, p66Shc, and mammalian target of rapamycin (TOR).21-
23 These genes integrate longevity pathways and metabolic signals in a complex 
interplay in which lifespan appears to be strictly dependent on substrate and energy 




epigenetic changes in the aforementioned signalling pathways can occur as a 
consequence of DM in HSPCs, leading to combined detrimental effects on 
myelopoiesis and cell mobilization. This new mechanistic understanding could inspire 
novel modalities to restore BM regenerative capacity and preserve proper 
myelopoiesis in people with DM.25 
 
Pathogenic phenomena upstream of mobilopathy 
In the last 10 years, our team has been exploring the hypothesis that DM-related 
peripheral complications, namely microangiopathy and neuropathy, could extend to 
the BM and thus contribute to altering HSPC viability and functionality.  
Initially, we demonstrated the presence of microangiopathy in BM of type 1 
diabetic mice.26 Rarefaction of capillaries and arterioles was associated with a 
depletion of HSPCs in the endosteal niche. This cell depletion was accompanied by 
increased oxidative stress, DNA damage, and activation of apoptosis. BM 
microangiopathy could be rescued by benfotiamine, which acts as a cofactor of 
transketolase thereby promoting the activity of the pentose phosphate pathway and 
reducing the accumulation of toxic metabolites of glycolysis.26  
We next confirmed the occurrence of microangiopathy in the BM of patients 
with type 2 DM and verified this was more pronounced in those with CLTI.27 To dissect 
the worsening effect of CTLI on the DM-induced BM damage, we compared BM 
samples from cohorts of patients (with or without DM) undergoing hip replacement 
surgery with those from CTLI patients requiring over-the-knee amputation. In the latter 
case, the BM was collected at the amputation level where viable tissue was still 
present. Analysis of microvascular density demonstrated a significant difference 




arterioles and sinusoids. There was a large decrease in vascular density in BM of 
patients with DM and this deficit was more pronounced in those with CTLI. We 
concluded that DM causes microangiopathy in human BM, with vascular rarefaction 
being aggravated by CLTI. In a multivariate analysis considering associated risk 
factors, microvascular rarefaction was predicted by the duration of DM and arterial 
hypertension, thus suggesting an interaction between the two conditions.27 Further 
investigation of different populations of vascular and perivascular cells (pericytes) 
revealed that both carry alterations in key molecular signalling pathways that control 
angiogenesis, permeability, and leukocyte trafficking.28, 29 Moreover, the rarefaction of 
microvessels was associated with apoptotic pauperization of CD34+ HSPCs and fat 
accumulation.27 The depletion of HSPCs was attributed to the creation of a hypoxic 
environment causing the downregulation of signallings that control the viability and 
proliferation/expansion of HSPCs.27 
Furthermore, in line with concept that perception of pain is often detrimentally 
abrogated in diabetic patients with neuropathy, we found substance-P (SP) expressing 
nociceptive fibres were also reduced in the BM of patients and mice with type 1 and 2 
DM.22 30 These preclinical studies provided experimental evidence suggesting that BM 
sensory neuropathy might contribute in impairing the mobilization of specific 
populations of HSPCs. In diabetic mice with acutely induced hindlimb ischemia, we 
could observe that spontaneous blood flow recovery was delayed compared with non-
diabetic mice. This expected difference was mirrored in diabetic mice by an altered 
gradient for SP between BM and the circulation and a reduced peripheral recruitment 
of populations of HSPCs responsive to SP.22 30  This adverse post-ischemic outcome 
was phenocopied in mice that had the BM transplanted with HSPCs lacking receptors 




Importantly, both sensory nerve rarefaction and ischemic limb healing were rescued 
by gene therapy with nerve growth factor (NGF) in diabetic mice.30 We concluded that, 
in patients with advanced diabetic complications, microangiopathy and sensory 
neuropathy could cooperate in jeopardizing HSPCs fate and function within the BM 
before they are liberated into the circulation. A recent review article has summarized 
the knowledge on neuropathy and inflammation in diabetic bone marrow.31 
 
DM drives stromal cells away from bone toward an adipogenic fate 
Patients with DM suffer problems with bones, including osteoporosis, more frequent 
fractures, and Charcot foot. The role of osteoblasts in DM-related osteoporosis is well 
acknowledged whereas the role of osteoclasts (OCLs) is still unclear. We found that 
type 1 diabetic mice have an increased number of active OCLs in trabecular bone. 
This was induced by the development of local hypoxia-induced acidosis in BM with 
consequent stimulation of transient receptor potential cation channel subfamily V 
member 1 (TRPV1).32 This receptor is expressed by various cell types, including 
neurons. Interestingly, treatment with TRPV1 receptor antagonists restored OCL 
activity and bone homeostasis. We concluded that the use of clinically available 
TRPV1 antagonists may provide a new means to combat bone problems associated 
with DM. 32  
Stromal cells resident in the BM have the capacity to develop into bone and 
adipose tissue and this balance is maintained through a finely tuned mechanism 
controlled by genetic and epigenetic factors. We recently reported that type 2 DM 
causes molecular and metabolic changes that relentlessly convert the marrow stroma 
into inflamed fat.33 The BM of people with DM, especially those affected by CLTI, 




and secrete large amounts of chemokines and adipokines, such as tumour-necrosis 
factor-α (TNFα) and monocyte chemoattractant protein-1/chemokine (C–C motif) 
ligand-2 (MCP-1/CCL2), promoting macrophage infiltration.33 CCL2 levels were also 
increased in the cell-free the BM lavage, suggesting that the chemokine could be 
released into the circulation.34 Moreover, we discovered a feedback loop wherein BM 
stromal cells from diabetic patients are more inclined to make adipocytes and, in turn, 
mature adipocytes fuel stromal cell differentiation into new fat cells via CCL2 (Figure 
1).34  
To verify the contribution of CCL2 to BM adipogenesis, we administered a 
CCR2 antagonist or its vehicle to obese diabetic mice. Importantly, antagonist-treated 
mice showed less BM fat, due to reduced adipocyte quantities and size and also 
resulted in improved control of the diabetic condition.34 
 
Involvement of BM HSPC dysfunction 
Prediction of clinical outcomes in diabetic patients suffering CLTI is unsatisfactory. We 
performed a prospective study investigating if the abundance and migratory activity of 
circulating CD34+ HSPCs can predict major amputation and cardiovascular death in 
type 2 diabetic patients undergoing percutaneous transluminal angioplasty for CLTI.35 
Results of the study were unexpected and intriguing. At 18-month follow-up, time-to-
event analysis of amputation and cardiovascular deaths showed no association with 
the quantity of the predictor. However, the ability of cells to migrate toward CXCL12 in 
vitro was strongly associated with cardiovascular death compared with event-free 
subjects. Multivariable regression model analysis showed that cell migration forecasts 
cardiovascular mortality independently of other validated predictors, such as age, 




glomerular filtration rate. In this model, the doubling of migrated cell counts increases 
the cardiovascular death hazard by 100%. We have confirmed the results in a follow-
up analysis at 6 years. We concluded that the new predictor could aid in the 
identification of high-risk patients with type 2 diabetes requiring special therapeutic 
care after revascularization. These data suggest an association between increased 
cell migration and cardiovascular mortality. However, the observed association was 
not enough to establish a cause-effect relationship. We further explored the hypothesis 
that DM could convert HSPCs into damaging cells, thereby amplifying the direct injury 
of DM on the vasculature. Results clearly demonstrated that, in HSPCs, vascular cells 
and peripheral blood of patients with DM and CLTI, several anti-angiogenic 
microRNAs, such as microRNA-15a and microRNA-16, were increased; whereas 
microRNAs with proangiogenic activity were reduced. 36, 37 Furthermore, the anti-
angiogenic microRNAs could be secreted and transferred to vascular cells thereby 
activating proapoptotic signalling in targeted cells. It is, therefore, possible that anti-
angiogenic CD34+ HSPCs able to migrate to areas of ongoing vascular damage can 
further accelerate the pathological process and increase the risk of cardiovascular 
death (Figure 2). 
 
Conclusions 
Optimal management of the diabetic foot ulceration involves a multimodality approach 
directed at regular foot care, early recognition, restoration of perfusion in case of 
ischemia and metabolic control. However, a “foot-centric” approach may be short-
sighted when considering the complex pathogenic phenomena occurring at a systemic 
level. This review highlights the necessity of considering the BM as a previously 
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Figure 1: DM forces stromal cells to an adipogenic fate in BM. The cartoon 
illustrates the proposed transition from normal to inflamed BM adipocytes (ADs), with 
triglyceride (TG) accumulation, activation of CCL2 signalling to enhance stromal cells 
conversion into new enlarged ADs and recruitment of macrophages. Damaged ADs 
release proinflammatory factors, TGs and free fatty acids (FFA) that can be captured 
by cardiovascular tissue. 
 
Figure 2. A vicious cycle affecting reparative mechanisms in DM. 
Microangiopathy and sensory neuropathy alter the BM niche, causing depletion and 
dysfunction of HSPCs and adipogenic transformation of stromal cells. Diabetic 
mobilopathy is associated with the release of cells that cause additional damage 
through secretion of anti-angiogenic and pro-apoptotic factors that are captured by the 
vascular endothelium. This can amplify the direct damage of metabolic disease on 
peripheral vessels. Inflammatory mediators from injured tissue (e.g. a diabetic foot 
ulcer) can reach the BM as well as other organs perpetuating a chronic low-grade 
systemic inflammation. Following angioplasty of CLTI, the presence of CD34+ cells 
characterized by high migratory activity identifies patients at high risk of cardiovascular 
mortality. The cause-effect relationship of this association remains undetermined, but 
it is possible that these cells contribute to persistent vascular damage. 
 
 
